MedTrace Logo

Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients

NCT01345370 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2016-01-29

No results posted yet for this study

Summary

Treatment for newly diagnosed glioblastomas currently involves surgical resection followed by Temozolomide chemotherapy with concomitant radiotherapy, and then 6 cycles of Temozolomide in adjuvant. According to many studies, only those patients not expressing the enzyme repair MGMT benefit from the adjunction of Temozolomide. Therefore, many patients receive unnecessary treatment. The aim of this project is to compare different techniques for analysis of MGMT in order to choose the approach with the best cost/utility ratio, which will allow the selection of patients likely to respond to TMZ chemotherapy during the first course of GBM treatment.

Conditions

Interventions

DRUG

Temozolomide

According to sites procedures

RADIATION

Radiation Therapy

According to sites procedures

Sponsors & Collaborators

  • Rennes University Hospital

    collaborator OTHER

  • Center Eugene Marquis

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2015-04-30
Completion
2015-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01345370 on ClinicalTrials.gov